image
Healthcare - Biotechnology - NASDAQ - US
$ 2.2
7.84 %
$ 37 M
Market Cap
-0.5
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one OCX stock under the worst case scenario is HIDDEN Compared to the current market price of 2.2 USD, OncoCyte Corporation is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one OCX stock under the base case scenario is HIDDEN Compared to the current market price of 2.2 USD, OncoCyte Corporation is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one OCX stock under the best case scenario is HIDDEN Compared to the current market price of 2.2 USD, OncoCyte Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
1.5 M REVENUE
56.89%
-25.1 M OPERATING INCOME
-39.67%
-27.8 M NET INCOME
61.89%
-23.3 M OPERATING CASH FLOW
48.81%
-932 K INVESTING CASH FLOW
78.53%
12.2 M FINANCING CASH FLOW
-65.97%
115 K REVENUE
10.58%
-13.5 M OPERATING INCOME
-191.77%
-13.5 M NET INCOME
-197.86%
-5.55 M OPERATING CASH FLOW
7.14%
-87 K INVESTING CASH FLOW
54.45%
-255 K FINANCING CASH FLOW
-2.59%
Balance Sheet OncoCyte Corporation
image
Current Assets 10.7 M
Cash & Short-Term Investments 9.43 M
Receivables 484 K
Other Current Assets 782 K
Non-Current Assets 64.2 M
Long-Term Investments 0
PP&E 5.44 M
Other Non-Current Assets 58.8 M
Current Liabilities 7.19 M
Accounts Payable 953 K
Short-Term Debt 665 K
Other Current Liabilities 5.58 M
Non-Current Liabilities 42.1 M
Long-Term Debt 2.2 M
Other Non-Current Liabilities 39.9 M
EFFICIENCY
Earnings Waterfall OncoCyte Corporation
image
Revenue 1.5 M
Cost Of Revenue 1.09 M
Gross Profit 413 K
Operating Expenses 25.6 M
Operating Income -25.1 M
Other Expenses 2.64 M
Net Income -27.8 M
RATIOS
27.48% GROSS MARGIN
27.48%
-1672.39% OPERATING MARGIN
-1672.39%
-1848.37% NET MARGIN
-1848.37%
-108.54% ROE
-108.54%
-37.09% ROA
-37.09%
-36.77% ROIC
-36.77%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis OncoCyte Corporation
image
Net Income -27.8 M
Depreciation & Amortization 1.68 M
Capital Expenditures -281 K
Stock-Based Compensation 6.57 M
Change in Working Capital -3.97 M
Others 851 K
Free Cash Flow -23.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets OncoCyte Corporation
image
Wall Street analysts predict an average 1-year price target for OCX of $2.33 , with forecasts ranging from a low of $0.5 to a high of $4.25 .
OCX Lowest Price Target Wall Street Target
0.5 USD -77.27%
OCX Average Price Target Wall Street Target
2.33 USD 6.06%
OCX Highest Price Target Wall Street Target
4.25 USD 93.18%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership OncoCyte Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
298 K USD 3
0-3 MONTHS
3.98 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
7.17 M USD 3
9-12 MONTHS
Date Value Insider Amount Avg Price
2 weeks ago
Jan 14, 2025
Bought 22.1 K USD
SMITH PATRICK W
10 percent owner
+ 10286
2.15 USD
2 weeks ago
Jan 14, 2025
Bought 208 USD
SMITH PATRICK W
10 percent owner
+ 100
2.08 USD
2 weeks ago
Jan 13, 2025
Bought 11.8 K USD
SMITH PATRICK W
10 percent owner
+ 5669
2.08 USD
1 month ago
Dec 26, 2024
Bought 192 K USD
SMITH PATRICK W
10 percent owner
+ 90219
2.13 USD
1 month ago
Dec 26, 2024
Bought 26.4 K USD
Arno Andrew
Director
+ 12500
2.108 USD
1 month ago
Dec 05, 2024
Bought 45.8 K USD
James Andrea S.
Chief Financial Officer
+ 20000
2.29 USD
4 months ago
Oct 02, 2024
Bought 100 K USD
James Andrea S.
Chief Financial Officer
+ 33670
2.97 USD
4 months ago
Oct 02, 2024
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
0 USD
4 months ago
Oct 02, 2024
Bought 3.88 M USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 1315339
2.948 USD
9 months ago
Apr 11, 2024
Bought 7.06 M USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 2420000
2.9164 USD
9 months ago
Apr 11, 2024
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
0 USD
9 months ago
Apr 11, 2024
Bought 10 K USD
Riggs Josh
CEO and President
+ 3390
2.95 USD
9 months ago
Apr 11, 2024
Bought 100 K USD
Arno Andrew
Director
+ 33898
2.95 USD
1 year ago
Jun 14, 2023
Bought 6.45 K USD
KINGSLEY ALFRED D
Director
+ 30000
0.2149 USD
1 year ago
Apr 05, 2023
Bought 200 K USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
+ 663000
0.3017 USD
1 year ago
Apr 03, 2023
Bought 8.09 M USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 26827638
0.3017 USD
1 year ago
Apr 03, 2023
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
0 USD
2 years ago
Dec 23, 2022
Bought 87.9 K USD
Arno Andrew
Director
+ 250000
0.3515 USD
2 years ago
Dec 23, 2022
Bought 24.7 K USD
Gutfreund John Peter
Director
+ 75000
0.3297 USD
2 years ago
Dec 22, 2022
Bought 7.12 K USD
KINGSLEY ALFRED D
Director
+ 25000
0.285 USD
2 years ago
Aug 17, 2022
Bought 17.4 K USD
Last Andrew J.
director:
+ 20000
0.87 USD
2 years ago
Aug 17, 2022
Bought 6.75 K USD
Arno Andrew
director:
+ 7500
0.9 USD
2 years ago
Aug 16, 2022
Bought 38.4 K USD
ANDREWS RONALD ASBURY
President & CEO
+ 40000
0.96 USD
2 years ago
Aug 15, 2022
Bought 4.85 K USD
KINGSLEY ALFRED D
director:
+ 5000
0.97 USD
2 years ago
Aug 15, 2022
Bought 23.2 K USD
Gutfreund John Peter
director:
+ 25000
0.93 USD
2 years ago
Aug 15, 2022
Bought 10 K USD
GRIFFITH MELINDA
director:
+ 10000
1 USD
2 years ago
Aug 15, 2022
Bought 9.98 K USD
Carter Jennifer L.
director:
+ 10500
0.95 USD
2 years ago
Aug 15, 2022
Bought 112 K USD
Arno Andrew
director:
+ 115523
0.97 USD
2 years ago
Aug 15, 2022
Bought 32.1 K USD
Arno Andrew
Director
+ 34477
0.93 USD
2 years ago
Jun 24, 2022
Sell 13.2 K USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
- 12517
1.0514 USD
2 years ago
Jun 24, 2022
Sell 13.2 K USD
Kamen Efrem
director:
- 12517
1.0514 USD
2 years ago
Jun 24, 2022
Sell 41.6 K USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
- 40464
1.0269 USD
2 years ago
Jun 24, 2022
Sell 11.5 K USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
- 10964
1.0514 USD
2 years ago
Jun 24, 2022
Sell 36.4 K USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
- 35441
1.0269 USD
2 years ago
Apr 14, 2022
Bought 72.6 K USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
+ 57630
1.26 USD
2 years ago
Apr 14, 2022
Bought 23.6 K USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
+ 19210
1.227 USD
2 years ago
Apr 14, 2022
Bought 116 K USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
+ 92370
1.26 USD
2 years ago
Apr 14, 2022
Bought 37.8 K USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
+ 30790
1.227 USD
2 years ago
May 18, 2022
Sell 9.27 K USD
Yu Li
VP Cntrllr/Prncpl Acctng Offcr
- 8128
1.14 USD
2 years ago
Apr 14, 2022
Bought 72.6 K USD
PURA VIDA INVESTMENTS, LLC
Director
+ 57630
1.26 USD
2 years ago
Apr 14, 2022
Bought 23.6 K USD
PURA VIDA INVESTMENTS, LLC
Director
+ 19210
1.227 USD
2 years ago
Apr 14, 2022
Bought 2.55 M USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
+ 1916419
1.3325 USD
2 years ago
Apr 14, 2022
Bought 2.55 M USD
PURA VIDA INVESTMENTS, LLC
Director
+ 1916419
1.3325 USD
2 years ago
Apr 14, 2022
Bought 116 K USD
PURA VIDA INVESTMENTS, LLC
Director
+ 92370
1.26 USD
2 years ago
Apr 14, 2022
Bought 37.8 K USD
PURA VIDA INVESTMENTS, LLC
Director
+ 30790
1.227 USD
2 years ago
Apr 14, 2022
Bought 2.22 M USD
PURA VIDA INVESTMENTS, LLC
Director
+ 1665898
1.3325 USD
2 years ago
Apr 14, 2022
Bought 2.22 M USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
+ 1665898
1.3325 USD
2 years ago
Apr 14, 2022
Bought 1.84 M USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
+ 1381438
1.3325 USD
2 years ago
Apr 14, 2022
Bought 1.84 M USD
PURA VIDA INVESTMENTS, LLC
Director
+ 1381438
1.3325 USD
2 years ago
Apr 14, 2022
Bought 1.47 M USD
PURA VIDA INVESTMENTS, LLC
Director
+ 958209
1.53 USD
2 years ago
Apr 14, 2022
Bought 1.47 M USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
+ 958209
1.53 USD
2 years ago
Apr 14, 2022
Bought 1.27 M USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
+ 832949
1.53 USD
2 years ago
Apr 14, 2022
Bought 1.27 M USD
PURA VIDA INVESTMENTS, LLC
Director
+ 832949
1.53 USD
2 years ago
Apr 14, 2022
Bought 1.02 M USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
+ 767952
1.3325 USD
2 years ago
Apr 14, 2022
Bought 1.02 M USD
PURA VIDA INVESTMENTS, LLC
Director
+ 767952
1.3325 USD
2 years ago
Apr 14, 2022
Bought 1.06 M USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
+ 690719
1.53 USD
2 years ago
Apr 14, 2022
Bought 1.06 M USD
PURA VIDA INVESTMENTS, LLC
Director
+ 690719
1.53 USD
2 years ago
Apr 14, 2022
Bought 587 K USD
PURA VIDA INVESTMENTS, LLC
Director
+ 383976
1.53 USD
2 years ago
Apr 14, 2022
Bought 587 K USD
PURA VIDA INVESTMENTS, LLC
10 percent owner
+ 383976
1.53 USD
2 years ago
Apr 14, 2022
Bought 1.02 M USD
Kamen Efrem
director:
+ 767952
1.3325 USD
2 years ago
Apr 13, 2022
Bought 8 M USD
BROADWOOD CAPITAL INC
director:
+ 6003752
1.3325 USD
2 years ago
Apr 14, 2022
Bought 8 M USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 6003752
1.3325 USD
2 years ago
Apr 14, 2022
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
0 USD
2 years ago
Mar 25, 2022
Bought 21 K USD
Ross Douglas T.
Chief Scientific Officer
+ 15000
1.4 USD
2 years ago
Mar 15, 2022
Bought 19.8 K USD
Paulsen Gisela
Chief Operating Officer
+ 16500
1.198 USD
2 years ago
Mar 15, 2022
Bought 64.1 K USD
ANDREWS RONALD ASBURY
Chief Executive Officer
+ 50000
1.283 USD
2 years ago
Mar 16, 2022
Bought 64.1 K USD
ANDREWS RONALD ASBURY
Chief Executive Officer
+ 50000
1.283 USD
2 years ago
Mar 16, 2022
Bought 47.6 K USD
Redmond Cavan M.
director:
+ 40000
1.189 USD
2 years ago
Mar 15, 2022
Bought 29.1 K USD
Levine Mitchell S
Chief Financial Officer
+ 25000
1.166 USD
3 years ago
Mar 19, 2021
Bought 52.7 K USD
ANDREWS RONALD ASBURY
Chief Executive Officer
+ 11000
4.7911 USD
3 years ago
Feb 05, 2021
Bought 2.7 M USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 600000
4.5 USD
3 years ago
Feb 05, 2021
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
0 USD
4 years ago
Jan 20, 2021
Bought 5 M USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 1460280
3.424 USD
4 years ago
Jan 20, 2021
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
0 USD
4 years ago
Dec 23, 2020
Sell 2.3 K USD
KINGSLEY ALFRED D
Director
- 900
2.55 USD
4 years ago
Dec 21, 2020
Sell 75 K USD
KINGSLEY ALFRED D
Director
- 30000
2.5 USD
4 years ago
Dec 22, 2020
Sell 19.4 K USD
KINGSLEY ALFRED D
Director
- 7652
2.54 USD
4 years ago
Dec 21, 2020
Sell 13.1 K USD
KINGSLEY ALFRED D
Director
- 5148
2.54 USD
5 years ago
Sep 12, 2019
Bought 20.1 K USD
Levine Mitchell S
CFO
+ 10000
2.006 USD
4 years ago
Sep 12, 2020
Bought 20.1 K USD
Levine Mitchell S
CFO
+ 10000
2.006 USD
4 years ago
Aug 03, 2020
Bought 6.65 K USD
Parker Albert P
Chief Operating Officer
+ 5000
1.3296 USD
4 years ago
Aug 03, 2020
Bought 6.53 K USD
KALAJIAN TONY T
Sr.VP/Chief Accounting Officer
+ 5000
1.3066 USD
4 years ago
Aug 03, 2020
Bought 6.53 K USD
KALAJIAN TONY T
Sr.VP/Chief Accounting Officer
+ 5000
1.3066 USD
4 years ago
Aug 03, 2020
Bought 53.9 K USD
ANDREWS RONALD ASBURY
Chief Executive Officer
+ 40000
1.347 USD
4 years ago
Aug 03, 2020
Bought 13.2 K USD
Levine Mitchell S
Chief Financial Officer
+ 10000
1.32 USD
4 years ago
Apr 24, 2020
Bought 2.38 M USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 1050000
2.27 USD
4 years ago
Apr 24, 2020
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
0 USD
4 years ago
Mar 31, 2020
Bought 42.7 K USD
ANDREWS RONALD ASBURY
CEO and President
+ 18000
2.372 USD
4 years ago
Mar 31, 2020
Bought 42.7 K USD
ANDREWS RONALD ASBURY
CEO and President
+ 18000
2.372 USD
4 years ago
Mar 30, 2020
Bought 61.5 K USD
ANDREWS RONALD ASBURY
CEO and President
+ 27216
2.258 USD
4 years ago
Mar 31, 2020
Bought 42.7 M USD
ANDREWS RONALD ASBURY
CEO and President
+ 18000
2372 USD
4 years ago
Mar 30, 2020
Bought 61.5 K USD
ANDREWS RONALD ASBURY
CEO and President
+ 27216
2.258 USD
5 years ago
Jan 02, 2020
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
0 USD
5 years ago
Jan 02, 2020
Bought 1.34 M USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 623090
2.156 USD
5 years ago
Jan 02, 2020
Bought 1.66 M USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 768376
2.156 USD
5 years ago
Jan 02, 2020
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
0 USD
5 years ago
Jan 02, 2020
Sell 5.14 M USD
Lineage Cell Therapeutics, Inc.
- 2383090
2.156 USD
5 years ago
Nov 13, 2019
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
0 USD
5 years ago
Nov 13, 2019
Bought 2 M USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 1176471
1.7 USD
5 years ago
Sep 17, 2019
Bought 108 K USD
Arno Andrew
Director
+ 50000
2.1626 USD
5 years ago
Sep 13, 2019
Bought 19.8 K USD
KALAJIAN TONY T
SVP-Chief Accounting Officer
+ 10000
1.98 USD
5 years ago
Sep 13, 2019
Bought 19.8 K USD
KALAJIAN TONY T
SVP-Chief Accounting Officer
+ 10000
1.98 USD
5 years ago
Sep 11, 2019
Sell 6.64 M USD
Lineage Cell Therapeutics, Inc.
10 percent owner
- 4000000
1.66 USD
5 years ago
Sep 11, 2019
Bought 3.32 M USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 2000000
1.66 USD
5 years ago
Sep 11, 2019
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
0 USD
5 years ago
Sep 12, 2019
Bought 20.1 K USD
Levine Mitchell S
Chief Financial Officer
+ 10000
2.006 USD
5 years ago
Jul 05, 2019
Sell 4.5 M USD
BIOTIME INC
10 percent owner
- 2250000
2 USD
5 years ago
Jul 02, 2019
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
2 USD
5 years ago
Feb 08, 2019
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
3.75 USD
6 years ago
Jul 26, 2018
Bought 10 K USD
ANNETT WILLIAM
President and CEO
+ 3500
2.86 USD
6 years ago
Jul 26, 2018
Bought 10.5 K USD
ANNETT WILLIAM
President and CEO
+ 3500
3 USD
6 years ago
Jul 26, 2018
Bought 50 K USD
ANDREWS RONALD ASBURY
Director
+ 17482
2.86 USD
6 years ago
Jul 26, 2018
Bought 52.4 K USD
ANDREWS RONALD ASBURY
Director
+ 17482
3 USD
6 years ago
Jul 26, 2018
Bought 10 K USD
Levine Mitchell S
Chief Financial Officer
+ 3495
2.86 USD
6 years ago
Jul 26, 2018
Bought 10.5 K USD
Levine Mitchell S
Chief Financial Officer
+ 3495
3 USD
6 years ago
Jul 26, 2018
Bought 150 K USD
Redmond Cavan M.
Director
+ 52447
2.86 USD
6 years ago
Jul 26, 2018
Bought 157 K USD
Redmond Cavan M.
Director
+ 52447
3 USD
6 years ago
Jul 26, 2018
Bought 2.5 K USD
HESTERBERG LYNDAL K.
Sr VP, Research & Development
+ 874
2.86 USD
6 years ago
Jul 26, 2018
Bought 2.62 K USD
HESTERBERG LYNDAL K.
Sr VP, Research & Development
+ 874
3 USD
6 years ago
Jul 26, 2018
Bought 20 K USD
Last Andrew J.
Director
+ 6993
2.86 USD
6 years ago
Jul 26, 2018
Bought 21 K USD
Last Andrew J.
Director
+ 6993
3 USD
6 years ago
Jul 26, 2018
Bought 150 K USD
Arno Andrew
Director
+ 52447
2.86 USD
6 years ago
Jul 26, 2018
Bought 157 K USD
Arno Andrew
Director
+ 52447
3 USD
6 years ago
Mar 28, 2018
Bought 0 USD
BROADWOOD PARTNERS, L.P.
10 percent owner
+ 0
1.26 USD
7. News
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine Will provide key regulatory and reimbursement support Will assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medical Officer. globenewswire.com - 3 weeks ago
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer Irvine, Calif., Jan. 8, 2025 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medical Officer. prismmediawire.com - 3 weeks ago
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney Medicare coverage expanded following study showing that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA) MolDX confirms eligibility for billing under current Local Coverage Determination (LCD) and Z-Code Up to 20% of patients will have detectable DSA within the first five years post kidney transplant, representing greater than 10,000 patients per year in the US.1 From time of onset of dnDSA, 24% of patients will lose their allograft within 3 years compared to the 96% five-year allograft survival for patients without DSA.1 Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection. IRVINE, Calif. globenewswire.com - 3 weeks ago
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney Irvine, Calif., January 6, 2025 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a leader in diagnostic technology, today announced a significant milestone in the advancement of patient care for kidney transplant patients. prismmediawire.com - 3 weeks ago
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings January 13-16, 2025, San Francisco, CA IRVINE, Calif., December 9, 2024 – PRISM MediaWire – Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. prismmediawire.com - 1 month ago
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. globenewswire.com - 1 month ago
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study IRVINE, Calif., Dec. 04, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. prismmediawire.com - 1 month ago
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. globenewswire.com - 1 month ago
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms IRVINE, Calif., Dec. 02, 2024 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft™, which was published in the journal Nephrology Dialysis Transplantation. prismmediawire.com - 1 month ago
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft™, which was published in the journal, Nephrology Dialysis Transplantation. globenewswire.com - 1 month ago
OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript OncoCyte Corporation (NASDAQ:OCX ) Q3 2024 Results Conference Call November 12, 2024 5:00 PM ET Company Participants Julie Silber - PCG Advisory Josh Riggs - President and CEO Andrea James - CFO Ekke Schutz - Chief Science Officer Conference Call Participants Joseph Conway - Needham Vidyun Bais - BTIG Operator Thank you for standing by. My name is Kayla, and I will be your conference operator today. seekingalpha.com - 2 months ago
8. Profile Summary

OncoCyte Corporation OCX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 37 M
Dividend Yield 0.00%
Description OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Contact 15 Cushing, Irvine, CA, 92618 https://oncocyte.com
IPO Date Dec. 30, 2015
Employees 43
Officers Ms. Sandra O'Donald Senior Vice President of Business Operations Dr. Michael D. West Ph.D. Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. & President of Biotime,Inc. Dr. Paul R. Billings FACP, M.D. Consulting Chief Medical Officer Mr. Joshua Riggs President, Chief Executive Officer & Director Mr. James Liu Senior Director, Controller & Principal Accounting Officer Ms. Andrea Susan James Chief Financial Officer Mr. Yuh-Min Chiang Ph.D. Chief Technology Officer Mr. Peter Hong Vice President, General Counsel & Secretary Dr. Ekkehard Schutz M.D., Ph.D. Chief Science Officer